Akero Therapeutics price target raised to $58 from $50 at Canaccord

Canaccord analyst Edward Nash raised the firm’s price target on Akero Therapeutics to $58 from $50 and keeps a Buy rating on the shares. The analyst said the increase is based on an adjustment in pricing to be in line with branded T2D injectables as well as an extension in the out-year of our model from 2029 to 2032.